Page 143 - 89Zr-Immuno-PET:Towards a Clinical Tool to Guide Antibody-based Therapy in Cancer
P. 143
CHAPTER 7
Performance of 89Zr-labeled-rituximab PET as an imaging biomarker to assess CD20 targeting:
a pilot study in patients with relapsed/refractory diffuse large B cell lymphoma
Yvonne W.S. Jauw Josée M. Zijlstra Daphne de Jong
Danielle J. Vugts Sonja Zweegman Otto S. Hoekstra Guus A.M.S. van Dongen Marc C. Huisman
PLoS ONE. 2017;12:e0169828.
